XLVS:LSE:LSE-Invesco Health Care S&P US Select Sector UCITS ETF (USD)

ETF | Others |

Last Closing

USD 675.265

Change

-0.83 (-0.12)%

Market Cap

USD 0.33B

Volume

185.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

+180.00 (+2.15%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+280.00 (+3.37%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

-1.50 (-0.80%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.27%)

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.04 (-0.24%)

USD 636.40B
0R1I:LSE NVIDIA Corp.

+5.05 (+0.54%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+5.75 (+0.28%)

USD 320.04B
0QZK:LSE Coca-Cola Co.

+0.40 (+0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.30 (+1.27%)

USD 258.54B

ETFs Containing XLVS:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.20% 56% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.20% 56% F 57% F
Trailing 12 Months  
Capital Gain 6.16% 47% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.16% 45% F 54% F
Trailing 5 Years  
Capital Gain 68.10% 85% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.10% 83% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 11.51% 77% C+ 77% C+
Dividend Return 11.51% 76% C+ 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.62% 65% D 78% C+
Risk Adjusted Return 108.36% 99% N/A 99% N/A
Market Capitalization 0.33B 64% D 55% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike